The white, round pill imprinted with 027 (often with an R or logo on the reverse side) is Alprazolam 0.25 mg, a generic equivalent of brand-name Xanax. It belongs to the triazolobenzodiazepine class of central nervous system (CNS) depressants and is a DEA Schedule IV controlled substance.
Pill Identification
Attribute – Visual / Clinical Properties
- Imprint –
027with a bisect score line on one side; manufacturer logo/letter (e.g.,Rfor Actavis/Teva) on the reverse - Color & Shape – White, round tablet
- Active Ingredient – Alprazolam 0.25 mg
- Drug Class – Benzodiazepine (CNS Depressant / Anxiolytic)
- DEA Schedule – Schedule IV Controlled Substance (C-IV)
- Common Labelers – Actavis Pharma, Teva Pharmaceuticals, Rising Pharma
Mechanism of Action
Alprazolam produces its therapeutic effects by binding to specific regulatory sites within the central nervous system:
- Receptor Modulation: Alprazolam acts as a positive allosteric modulator at the (gamma-aminobutyric acid type A) receptor-chloride channel complex.
- Increased Chloride Conductance: By enhancing the binding affinity of GABA (the brain’s primary inhibitory neurotransmitter), it increases the opening frequency of neuronal chloride channels.
- Hyperpolarization: The resulting influx of chloride ions leads to membrane hyperpolarization, dampening neuronal excitability throughout the limbic and cortical pathways.
- Clinical Effects: This rapid central inhibition provides anxiolytic, sedative, muscle-relaxant, and anticonvulsant effects, with a rapid onset of action.
Indications and Dosing Guidelines
Alprazolam 0.25 mg tablets are FDA-approved for:
- Generalized Anxiety Disorder (GAD): Relief of short-term anxiety symptoms or anxiety associated with depression.
- Panic Disorder: Treatment of panic disorder, with or without agoraphobia.
Standard Dosage
- Anxiety Disorders: The usual starting dose is 0.25 mg to 0.5 mg administered three times daily. Doses may be titrated at intervals of 3 to 4 days up to a maximum recommended total daily dose of 4 mg/day in divided doses.
- Panic Disorder: Typically initiated at 0.5 mg three times daily, titrated upwards as needed (frequently requiring 3 to 6 mg/day, and occasionally up to 10 mg/day under close specialist supervision).
- Elderly or Hepatically Impaired Patients: Starting dose is reduced to 0.25 mg taken 2 or 3 times daily to avoid excessive sedation and ataxia.
Common and Serious Side Effects
Common Adverse Effects
- Sedation & Somnolence: Drowsiness, fatigue, sluggish reflexes.
- Impaired Motor Function: Ataxia, unsteadiness, poor coordination, and dizziness.
- Cognitive Effects: Memory impairment (anterograde amnesia), confusion, and slurred speech.
- Gastrointestinal / Other: Constipation, dry mouth, changes in appetite or weight.
Serious Adverse Effects
- Severe Respiratory Depression: Dangerously slowed or shallow breathing, particularly when combined with other depressants.
- Paradoxical Reactions: Acute agitation, rage, irritability, restlessness, or hallucinations (more frequent in elderly or psychiatric populations).
- Severe Physical Dependence & Seizures: Rapid emergence of life-threatening withdrawal upon abrupt discontinuation.
FDA Boxed Warnings and Precautions
The FDA requires a Boxed Warning on all alprazolam formulations highlighting three primary risks:
Concomitant Use with Opioids
Concurrent use of benzodiazepines and opioids (such as oxycodone, hydrocodone, morphine, or illicit fentanyl) may result in profound sedation, respiratory arrest, coma, and death. Combined therapy should be strictly reserved for situations where alternative non-opioid or non-benzodiazepine options are inadequate.
Abuse, Misuse, and Addiction
Alprazolam carries a substantial risk of abuse, misuse, and addiction, which can lead to overdose and death. Risks are elevated in individuals with a history of substance use disorder.
Physical Dependence and Severe Withdrawal
Regular use – even at prescribed therapeutic doses – can produce physical dependence within a few weeks. Abrupt discontinuation or rapid dose reduction must be avoided because it can trigger severe withdrawal symptoms, including:
- Generalized tonic-clonic seizures
- Delirium, hallucinations, and tremors
- Rebound anxiety and severe insomnia
- Autonomic hyperactivity (tachycardia, hypertension, diaphoresis)
- Tapering Mandate: Discontinuation requires a gradual, medically supervised dose taper (often reducing no more than 0.5 mg every 3 days, or slower).
Major Drug Interactions and Contraindications
- Potent CYP3A4 Inhibitors: Alprazolam is heavily metabolized by the hepatic enzyme CYP3A4. Concomitant use with strong CYP3A inhibitors – such as ketoconazole, itraconazole, or clarithromycin – is contraindicated because it drastically increases alprazolam blood concentrations.
- Acute Narrow-Angle Glaucoma: Alprazolam is contraindicated in patients with untreated acute narrow-angle glaucoma.
- Pregnancy: Crosses the placenta and may cause fetal harm, neonatal sedation, or neonatal withdrawal syndrome (floppy infant syndrome).